Nras Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| NRAS Protein | |
|---|---|
| Protein Name | NRAS Protein |
| Gene | NRAS |
| UniProt ID | P01111 |
| PDB IDs | 1R3Q, 1CRQ, 1Q21 |
| Molecular Weight | 21.2 kDa |
| Subcellular Localization | Cell membrane, Cytoplasm, Golgi apparatus |
| Protein Family | Ras family |
The NRAS protein is a small GTPase belonging to the Ras family of proto-oncogenes. It functions as a molecular switch, cycling between an active GTP-bound state and an inactive GDP-bound state. When active, NRAS recruits and activates downstream effectors including RAF kinases, PI3K, and RalGEFs. In neurons, NRAS regulates synaptic plasticity, learning and memory through MAPK/ERK and PI3K/AKT signaling pathways. Dysregulated NRAS signaling contributes to neurodegenerative processes by affecting protein synthesis, cytoskeletal dynamics, and cell survival pathways.
NRAS is a small GTPase that acts as a molecular switch to regulate cell signaling, proliferation, and differentiation.
NRAS is a 189-amino acid protein with a conserved GTPase domain. It cycles between active GTP-bound and inactive GDP-bound states. The protein has switch I (residues 30-40) and switch II (residues 60-76) regions that undergo conformational changes during the GTPase cycle. NRAS is anchored to membranes via C-terminal CAAX motif prenylation (farnesylation).
NRAS regulates the MAPK/ERK and PI3K/AKT signaling pathways. In neurons, NRAS is involved in synaptic plasticity, learning, and memory. It plays roles in neuronal differentiation and axon guidance. Dysregulated NRAS signaling contributes to neurodegeneration through effects on protein synthesis, cytoskeletal dynamics, and cell survival. NRAS mutations that lock it in the active GTP-bound state can lead to aberrant signaling.
NRAS mutations are associated with Noonan syndrome and various cancers. In neurodegeneration, altered Ras-MAPK signaling contributes to synaptic dysfunction in AD, dopaminergic neuron vulnerability in PD, and transcriptional dysregulation in HD.
Farnesyltransferase inhibitors (tipifarnib, lonafarnib) have been developed to block Ras prenylation. MEK inhibitors (trametinib, cobimetinib) target downstream MAPK signaling. These have primarily been tested in cancer but may have applications in neurodegeneration.
The study of Nras Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.